vs

Side-by-side financial comparison of Array Technologies, Inc. (ARRY) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Array Technologies, Inc. is the larger business by last-quarter revenue ($226.0M vs $207.3M, roughly 1.1× Ultragenyx Pharmaceutical Inc.). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -17.9%). Array Technologies, Inc. produced more free cash flow last quarter ($36.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 21.4%).

ATI Technologies Inc. was a Canadian semiconductor technology corporation based in Markham, Ontario, that specialized in the development of graphics processing units and chipsets. Founded in 1985, the company listed publicly in 1993 and was acquired by AMD in 2006. As a major fabless semiconductor company, ATI conducted research and development in-house and outsourced the manufacturing and assembly of its products. With the decline and eventual bankruptcy of 3dfx in 2000, ATI and its chief ri...

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

ARRY vs RARE — Head-to-Head

Bigger by revenue
ARRY
ARRY
1.1× larger
ARRY
$226.0M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+43.8% gap
RARE
25.9%
-17.9%
ARRY
More free cash flow
ARRY
ARRY
$136.9M more FCF
ARRY
$36.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
21.4%
ARRY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARRY
ARRY
RARE
RARE
Revenue
$226.0M
$207.3M
Net Profit
$-128.6M
Gross Margin
8.6%
Operating Margin
-65.5%
-54.7%
Net Margin
-62.0%
Revenue YoY
-17.9%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-1.06
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARRY
ARRY
RARE
RARE
Q4 25
$226.0M
$207.3M
Q3 25
$393.5M
$159.9M
Q2 25
$362.2M
$166.5M
Q1 25
$302.4M
$139.3M
Q4 24
$275.2M
$164.6M
Q3 24
$231.4M
$139.5M
Q2 24
$255.8M
$147.0M
Q1 24
$153.4M
$108.8M
Net Profit
ARRY
ARRY
RARE
RARE
Q4 25
$-128.6M
Q3 25
$33.5M
$-180.4M
Q2 25
$43.3M
$-115.0M
Q1 25
$16.7M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-141.4M
$-133.5M
Q2 24
$25.7M
$-131.6M
Q1 24
$2.2M
$-170.7M
Gross Margin
ARRY
ARRY
RARE
RARE
Q4 25
8.6%
Q3 25
26.9%
Q2 25
26.8%
Q1 25
25.3%
Q4 24
28.5%
Q3 24
33.8%
Q2 24
33.6%
Q1 24
35.9%
Operating Margin
ARRY
ARRY
RARE
RARE
Q4 25
-65.5%
-54.7%
Q3 25
11.6%
-106.9%
Q2 25
12.8%
-64.8%
Q1 25
9.0%
-102.6%
Q4 24
-51.7%
-74.3%
Q3 24
-57.3%
-94.6%
Q2 24
15.5%
-79.1%
Q1 24
5.5%
-151.9%
Net Margin
ARRY
ARRY
RARE
RARE
Q4 25
-62.0%
Q3 25
8.5%
-112.8%
Q2 25
11.9%
-69.0%
Q1 25
5.5%
-108.5%
Q4 24
-80.9%
Q3 24
-61.1%
-95.7%
Q2 24
10.0%
-89.5%
Q1 24
1.4%
-156.8%
EPS (diluted)
ARRY
ARRY
RARE
RARE
Q4 25
$-1.06
$-1.28
Q3 25
$0.12
$-1.81
Q2 25
$0.19
$-1.17
Q1 25
$0.02
$-1.57
Q4 24
$-0.94
$-1.34
Q3 24
$-1.02
$-1.40
Q2 24
$0.08
$-1.52
Q1 24
$-0.07
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARRY
ARRY
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$244.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-206.3M
$-80.0M
Total Assets
$1.5B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARRY
ARRY
RARE
RARE
Q4 25
$244.4M
$421.0M
Q3 25
$221.5M
$202.5M
Q2 25
$377.3M
$176.3M
Q1 25
$348.3M
$127.1M
Q4 24
$363.0M
$174.0M
Q3 24
$332.4M
$150.6M
Q2 24
$282.3M
$480.7M
Q1 24
$287.6M
$112.3M
Stockholders' Equity
ARRY
ARRY
RARE
RARE
Q4 25
$-206.3M
$-80.0M
Q3 25
$-46.7M
$9.2M
Q2 25
$-70.9M
$151.3M
Q1 25
$-97.8M
$144.2M
Q4 24
$-118.1M
$255.0M
Q3 24
$64.5M
$346.8M
Q2 24
$200.0M
$432.4M
Q1 24
$231.2M
$140.3M
Total Assets
ARRY
ARRY
RARE
RARE
Q4 25
$1.5B
$1.5B
Q3 25
$1.6B
$1.2B
Q2 25
$1.5B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.4B
$1.5B
Q3 24
$1.6B
$1.5B
Q2 24
$1.7B
$1.6B
Q1 24
$1.6B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARRY
ARRY
RARE
RARE
Operating Cash FlowLast quarter
$43.6M
$-99.8M
Free Cash FlowOCF − Capex
$36.2M
$-100.8M
FCF MarginFCF / Revenue
16.0%
-48.6%
Capex IntensityCapex / Revenue
3.3%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$79.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARRY
ARRY
RARE
RARE
Q4 25
$43.6M
$-99.8M
Q3 25
$27.4M
$-91.4M
Q2 25
$43.8M
$-108.3M
Q1 25
$-13.1M
$-166.5M
Q4 24
$57.6M
$-79.3M
Q3 24
$44.9M
$-67.0M
Q2 24
$4.0M
$-77.0M
Q1 24
$47.5M
$-190.7M
Free Cash Flow
ARRY
ARRY
RARE
RARE
Q4 25
$36.2M
$-100.8M
Q3 25
$21.9M
$-92.7M
Q2 25
$37.2M
$-110.7M
Q1 25
$-15.4M
$-167.8M
Q4 24
$55.9M
$-79.5M
Q3 24
$43.9M
$-68.6M
Q2 24
$1.8M
$-79.0M
Q1 24
$45.1M
$-193.9M
FCF Margin
ARRY
ARRY
RARE
RARE
Q4 25
16.0%
-48.6%
Q3 25
5.6%
-58.0%
Q2 25
10.3%
-66.5%
Q1 25
-5.1%
-120.5%
Q4 24
20.3%
-48.3%
Q3 24
19.0%
-49.2%
Q2 24
0.7%
-53.7%
Q1 24
29.4%
-178.2%
Capex Intensity
ARRY
ARRY
RARE
RARE
Q4 25
3.3%
0.5%
Q3 25
1.4%
0.8%
Q2 25
1.8%
1.5%
Q1 25
0.8%
1.0%
Q4 24
0.6%
0.1%
Q3 24
0.5%
1.2%
Q2 24
0.8%
1.4%
Q1 24
1.6%
3.0%
Cash Conversion
ARRY
ARRY
RARE
RARE
Q4 25
Q3 25
0.82×
Q2 25
1.01×
Q1 25
-0.78×
Q4 24
Q3 24
Q2 24
0.15×
Q1 24
21.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARRY
ARRY

Array Legacy Operations Segment$212.0M94%
STI Operations Segment$14.0M6%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons